Bioxtreme Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Net Worth 112.23%
- Total Assets 10504.29%
About Bioxtreme Pharma
Bioxtreme Pharma Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 April 2021 (Three years and ten months 2 days old ). Its registered office is in Panchkula, Haryana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kali Jaiswal and Avadhesh Singh serve as directors at the Company.
Company Details
-
Location
Panchkula, Haryana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230HR2021PTC094502
-
Company No.
094502
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Apr 2021
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Bioxtreme Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kali Jaiswal
|
Director | 15-Apr-2021 | Current |
|
Avadhesh Singh
|
Director | 15-Apr-2021 | Current |
Financial Performance of Bioxtreme Pharma.
Bioxtreme Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 112.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioxtreme Pharma?
Unlock access to Bioxtreme Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Human Biolife India Private LimitedKali Jaiswal is a mutual person
-
Nexwin Pharma Private LimitedKali Jaiswal is a mutual person
-
Sparkbless Pharma Private Limited
Kali Jaiswal is a mutual person
-
Anshi Infratech Private Limited
Avadhesh Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bioxtreme Pharma?
Bioxtreme Pharma has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioxtreme Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioxtreme Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.